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Lysosomal regulation is a poorly understood mechanism that is central to degradation and recycling processes. Here we report
that LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and mTOR activator 1) downregulation affects lysosomal activation,
through mechanismsthatare notsolely due tomTORC1 inhibition.LAMTOR1depletion stronglyincreases lysosomal structures
that display a scattered intracellular positioning. Despite their altered positioning, those dispersed structures remain overall
functional: (i) the trafﬁcking and maturation of the lysosomal enzyme cathepsin B is not altered; (ii) the autophagic ﬂux, ending
up in the degradation of autophagic substrate inside lysosomes, is stimulated. Consequently, LAMTOR1-depleted cells face an
aberrant lysosomal catabolism that produces excessive reactive oxygen species (ROS). ROS accumulation in turn triggers
p53-dependent cell cycle arrest and apoptosis. Both mTORC1 activity and the stimulated autophagy are not necessary to
this lysosomal cell death pathway. Thus, LAMTOR1 expression affects the tuning of lysosomal activation that can lead to
p53-dependent apoptosis through excessive catabolism.
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Lysosomes serve as the important intracellular function of
compartmentalizingpH-dependentdegradation.Theyreceive
extracellular components via endocytosis and intracellular
material through autophagy or the biosynthetic pathway.
1,2
These catabolic functions are essential regulators of cellular
homeostasis, and lysosomal dysfunction is implicated in
various pathological processes including neurodegenerative
diseases.
3 Being part of a highly dynamic endocytic system
that implicates constant exchange of incoming and outgoing
membranes and multiple fusion events, cellular mechanisms
regulating lysosomal maturation and activity remain incom-
pletely understood.
2 Growing evidence indicates that lyso-
some positioning in cells can modulate lysosomal function.
4–6
For instance, their clustering in the perinuclear area facilitates
autophagy,
6 probably because of the spatially-restricted
increased concentration of lysosomes available for fusion
with autophagosomes.
Recently, we and others have simultaneously identiﬁed
LAMTOR1 (late endosomal/lysosomal adaptor MAPK and
mTOR activator 1), a novel adaptor of the lysosomal
membrane.
5,7–9 This lipidated protein anchors on the
surface of lysosomes the protein complex that drives amino
acid-dependent mTORC1 activation.
9 The activation status
of mTORC1 depends not only on whether it is bound to
lysosomes, but also on lysosomal positioning at the cell
periphery.
6 LAMTOR1 also serves as an essential anchor
for the p14-MP1–MEK–ERK pathway in late endosomes/
lysosomes.
5 Its loss results in redistribution of lysosomes
throughout the cytoplasm, which is associated with altera-
tions in the processing of lysosomes and impaired cycling of
rab11-positive recycling endosomes.
5,10 These defects are
attributed to the downregulation of both late endosomal-
associated MEK–ERK activity
5 and mTORC1 activity.
10
Noticeably, this altered endosomedynamics likely contributes
to the perturbation in cellular free cholesterol homeostasis
associated with LAMTOR1 depletion.
8,10 Lastly, LAMTOR1
may also regulate actin remodeling by activating RhoA and
RhoC through its binding to p27
kip1.
7,11
In this study, we show that the endolysosomal dysfunctions
induced by LAMTOR1 depletion encompass an unexpected
excessive catabolism that triggers a lysosomal reactive
oxygen species (ROS)–p53 cell death pathway. These
ﬁndings may help to better understand the pathologies
associated with lysosomal dysfunction such as certain
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Results
LAMTOR1 depletion induces p53-mediated cell cycle
arrest and apoptosis, independently of mTORC1 regula-
tion. During the course of previous studies,
8 we found that
LAMTOR1 depletion via short interfering RNA (siRNA)-
mediated knockdown led, within 72h, to reduced SHEP cell
numbers (Figure 1a) associated with apparent cell death.
Cell cycle analysis of LAMTOR1-depleted cells, using pulse
50-bromo-2-deoxyuridine (BrdU) labeling, showed a lower
percentage of cells entering into S phase compared with
control siRNA (Figure 1b), conﬁrming a decreased cell cycle
entry. Flow cytometric analysis of annexin V binding showed
an increase in cellular staining that could be prevented by the
pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-
(O-methyl)-ﬂuoromethylketone (zVAD), but not by the
z-phe-ala ﬂuoromethylketone (zFA) inhibitor control
(Figure 1c), indicating that LAMTOR1-depleted SHEP cells
were concomitantly undergoing apoptosis. Given that SHEP
cells are wild type for p53 and that p53 is an important cell
cycle and cell death regulator,
12 it was reasoned that the
observed cellular response might be due to p53 activation.
Both an increase in p53 expression and in p21 expression, a
cyclin-dependent kinase inhibitor whose gene is transcrip-
tionally activated by p53, could be readily observed in
LAMTOR1-depleted SHEP cells (Figure 1d). LAMTOR1
silencing-induced biological outcomes are observed irre-
spective of the use of two independent siRNA A or B (as
exempliﬁed in Figure 1d), or when using of a pool of siRNA A
and B, which further reduces off-target silencing due to
competition among the siRNAs
13 (Supplementary Figure S1).
To conﬁrm that LAMTOR1 depletion-induced apoptosis is
elicited through p53, we compared an isogenic set of human
colon adenocarcinoma cell lines (HCT116) differing only
in their p53 status.
14 The parental HCT116 line, containing
wild-type p53 (p53
þ/þ) exhibited a marked increase in
annexin V staining upon LAMTOR1 depletion (Figure 2a).
However, the p53-deﬁcient derivative (p53
 / ) was much
less sensitive to LAMTOR1 depletion. Consistently, both an
increase in p53 expression and in p21 expression was
detected in the parental HCT116 line, but not in its p53
 / 
counterpart (Figure 2b). Therefore, LAMTOR1 depletion
induces p53-dependent cell cycle inhibition and apoptosis.
LAMTOR1 depletion abrogates mTORC1 activation.
9 To
testwhetherp53activationislinkedtodysfunctionalmTORC1
regulation, we investigated the effect of LAMTOR1 depletion
in the non-tumorigenic human epithelial cell line MCF10-A in
which the endogenous raptor (mTORC1) or rictor (mTORC2)
havebeenknockeddownusingspeciﬁcshRNA.
15Thesecells
have signiﬁcantly reduced levels (490% reduction) of each of
the targeted proteins (Figure 2c, left panel). In the different
shRNA expressing cells, LAMTOR1 depletion could still
increase p53 and p21 expressions (Figure 2c, right panel).
Thus, mTORC1 inhibition due to LAMTOR1 depletion is not
necessary to trigger p53 activation.
Figure 1 LAMTOR-1 depletion induces an increase in both p53 and p21 expression. SHEP cells were transfected with scrambled or LAMTOR1 (B) siRNAs, and viable
cellswerecounted(a)orstainedwith BrdUandPI forcellcycleanalysis(b), 72h aftertransfection.ValuesaremeansþS.E.M.ofthreeindependentexperiments.**Po0.01
using Mann–Whitney test. (c) FACS analysis of Annexin V/PI staining of SHEP cells transfected with the indicated siRNAs as above and treated or not with zFA (20mM) or
zVAD (20mM) for 72h; n¼3. **Po0.01 using Mann–Whitney test. (d) SHEP cells transfected with scrambled or LAMTOR1 (A or B) siRNAs were analyzed for expression
levels of P53, P21, LAMTOR1 and actin proteins by western blotting; n¼5
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Cell Death and DiseaseLAMTOR1 depletion causes lysosomal activation. As an
initial step to characterize the mechanism by which LAM-
TOR1 depletion induces p53 activation, we used electron
microscopy to assess intracellular perturbations at the
ultrastructural level. Compared with control siRNA-treated
cells, LAMTOR1 depletion induced numerous intracellular
vesicles of different sizes and shapes (Figure 3a). Many
of these vesicles met standard morphologic criteria for
autophagosomes, autolysosomes and lysosomes.
16,17 The
increase in autophagic and lysosomal structures upon
LAMTOR1 depletion is consistent with an abrogated
mTORC1 activation that stimulates the autophagic pro-
cess.
18,19 Intriguingly, however, the increased lysosomal
structures were scattered throughout the cytoplasm,
instead of being clustered in the perinuclear area to
facilitate autophagosome–lysosome fusion.
6 Therefore, the
autophagic process might not be fully functional in these
cells. In addition, LAMTOR1 depletion can affect the
processing and the ﬁnal maturation of lysosomes.
5,10 Thus,
we evaluated the extent of these lysosomal dysfunctions that
might be linked with p53 activation.
First, we assessed the maturation and levels of the major
lysosomal enzyme cathepsin D. Cathepsin D is transported
from the Golgi through late endosomes to lysosomes.
20 Its
mature chains (34 and 14kDa) are produced by the cleavage
of the intermediate chain (48kDa) upon exposure to the acidic
environment in lysosomes. Importantly, any change in its
mature forms reﬂects altered late endocytic trafﬁcking or
perturbed lysosomal maturation. Consistent with previous
report,
5 LAMTOR1 depletion disrupted accumulation of
cathepsin D-positive lysosomal structures in the perinuclear
region and dispersed them throughout the cytoplasm
(Figure 3b, see also Supplementary Figure S4). Despite this
dispersion, LAMTOR1 depletion increased the level of mature
cathepsin34kDachain(Figure3c,theantibodyuseddoesnot
recognize the 14kDa chain) without increasing its intermedi-
ate or immature forms (Figure 4b). The increase in mature
cathepsin D was not speciﬁc to SHEP cells as it was
recapitulated in the p53
þ/þ HCT116 line (Supplementary
Figure S2B). Thus, the altered spatial organization of
lysosomes does not signiﬁcantly impair lysosomal proces-
sing. Together with the augmented number of lysosomal
structures, the increased levels of both mature cathepsin D
and lysosome-associated membrane protein-1 (LAMP-1)
(Figure 3c) are consistent with an expansion of the lysosomal
system.
Second, to evaluate the proper function of lysosomes, we
assessed autophagic ﬂux, that is, the dynamic process of
autophagosome synthesis, their fusion with lysosomes, and
thedegradationofautophagicsubstratesinsidethelysosome.
We analyzed the conversion and turnover of the autophagic
marker microtubule-associatedprotein lightchain3 (LC3)and
the degradation of the autophagic-speciﬁc substrate p62.
21
LC3-II is a lipidated form of LC3-I that inserts into autophagic
membranes. P62 is selectively incorporated into autophago-
somes through direct binding to LC3-II. Both markers are
eventually degraded by lysosomal hydrolases following
fusion of autophagosomes with lysosomes. Compared with
control siRNA-treated cells, LAMTOR1-depleted cells dis-
played increased levels of LC3-I and to a lesser extent of
LC3-II, and decreased levels of p62 (Figure 3d). The
lysosomotropic agent chloroquine (CQ) is an alkylamine that
accumulates in the lysosome and neutralizes the lysosomal
acidity by its weak base property,
22 thereby reducing
lysosomal activity. In the presence of CQ, the amounts of
both LC3-II and p62 were substantially increased. Consistent
with the current understanding of LC3 and p62 ﬂux,
21 these
resultsindicatethatdespiteascatteredlysosomalpositioning,
the autophagic ﬂux is not substantially altered during
LAMTOR1 depletion.
Therefore, despite an altered lysosome positioning, we
present three lines of evidence (electron microscopic,
lysosomal hydrolase and autophagic analysis) that consis-
tently support the notion that LAMTOR1 depletion results in
expansion of an overall functional lysosomal system.
Figure 2 LAMTOR-1 depletion induces p53-mediated apoptosis. (a) Repre-
sentative FACS analysis of Annexin V/PI staining of HCT116 cells transfected with
scrambled or LAMTOR1 (B) siRNAs for 36h; n¼3. **Po0.01 using Mann–
Whitneytest.(b)HCT116cellstransfectedwithscrambledorLAMTOR1(B)siRNAs
for 36h were analyzed for expression levels of P53, P21, LAMTOR1 and actin
proteins by western blotting; n¼4. (c) MCF10-A cells were transfected with
scrambled shRNA plasmid (shCtrl) or shRNA plasmids targeted against Rictor or
Raptor. The corresponding protein expression levels are shown in the left panel.
These cells further transfected with scrambled or LAMTOR1 (A) siRNAs for 72h
wereanalyzedforexpressionlevelsofP53,P21,LAMTOR1andactinproteins(right
panel); n¼3
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Cell Death and DiseaseLysosomal activation generates ROS. Lysosomal cata-
bolism is recognized as a potent source of ROS.
23,24 Using
the ﬂuorescent ROS indicator dichlorodihydroﬂuorescein
diacetate (H2DCF-DA), we next assessed whether the
stimulated lysosomal activation could increase the intra-
cellular levels of ROS. We found that LAMTOR1 depletion
Figure 3 LAMTOR1 depletion induces lysosomal expansion. (a) Electron microscopy of SHEP cells transfected with scrambled siRNA (top panels), or with LAMTOR1
siRNA B (middle and bottom panels). Scale bars are indicated. Autophagosomes (white arrows), autolysosomes (black arrows) and lysosomes (arrow heads). (b) Confocal
images of representative cathepsin D immuno-staining in SHEP cells transfected with scrambled or LAMTOR1 (B) siRNAs. Scale bar¼ 10mm. (c) SHEP cells were
transfectedwithscrambledorLAMTOR1(B)siRNAsfortheindicatedtimesandtheexpressionlevelsofP53,P21,maturecathepsinD,LAMP-1andLAMTOR1proteinswere
analyzedby westernblotting; n¼3. (d)SHEPcellstransfectedwith scrambledor LAMTOR1(B) siRNAsfor 72h,werefurther treatedor notduringthelast 6h with 20mMC Q
to inhibit lysosomal activity. Expression levels of LC3-I, LC3-II, P62, LAMTOR1 and actin proteins were analyzed by western blotting; n¼4
Figure4 TheincreasedlysosomalactivitygeneratesROS.(a)RepresentativeFACShistogramsofH2DCF-DAanalysisofscrambledorLAMTOR1(B)siRNA-transfected
SHEP cells for 72h, treated or not with 2.5mMo fC Q ;n¼5. (b) LAMTOR1 (B) siRNA-treated SHEP cells were treated with indicated concentrations of CQ for 72h. The
maturation process of cathepsin D was analyzed by western blotting. Pro, pro-cathepsin D; Int, intermediate form of cathespsin D; Mat, mature form of cathespsin D; n¼2( c)
UntransfectedortransfectedSHEPcellswiththeindicatedsiRNAs(LAMTOR1siRNAB)for72h,wereanalyzedforexpressionlevelsofcathepsinD,LC3-I,LC3-II,p62,Beclin1,
LAMTOR1, and actin by western blotting n¼2. (d) Representative FACS histograms of H2DCF-DA analysis of SHEP cells transfected with the indicated siRNAs for 72h; n¼5
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Cell Death and Diseaseevoked an increased ROS production as compared with
control siRNA (Figure 4a). To examine whether this
increased ROS production was due to a stimulated lysoso-
mal catabolism, we used the lysosomal activity inhibitor CQ.
As a parameter of lysosomal degradative capacity, we
examined the pH-sensitive cleavage of cathepsin D. Con-
centrations above 2.5mM CQ completely blocked cathepsin
D cleavage, allowing only the detection of the pro-cathepsin
D intermediate chains (Figure 4b). As previously reported,
25
these CQ concentrations also induced signiﬁcant cell death
(data not shown). In contrast, cellular treatment with 2.5mM
CQ for 72h, signiﬁcantly reduced the appearance of the
34kDa mature chain of cathepsin D (Figure 4b), without
affecting the viability of SHEP cells (Figure 5a). In these cells
that display a reduced lysosomal degradative capacity,
LAMTOR1 depletion could no longer trigger ROS production
(Figure 4a). A reproducible, albeit less robust increase in
ROS production was also demonstrated in p53
þ/þ HCT116
line upon LAMTORT1 depletion (Supplementary Figure S2C).
This ROS production was also prevented by low doses
of CQ (Supplementary Figure S2B and S2C). Thus, these
results strongly support a functional link between an
increased lysosomal activity and ROS production.
We then evaluated the contribution of the autophagic ﬂux,
which increases lysosomal catabolism, to ROS production.
Beclin1 and autophagy-related gene 5 (ATG5) are an
important autophagic components.
21 We found that Beclin1
siRNA efﬁciently down-regulated Beclin1 protein expression,
and consequently limited the increase in LC3-I and LC3-II and
the decrease in p62, upon LAMTOR1 silencing (Figure 4c).
However, under this condition of impaired autophagic
ﬂux, both ROS production (Figure 4d) and the increase in
cathepsin D (Figure 4c) remained unaffected. It is
of note that the reduced cellular viability of LAMTOR1-
depleted cells was also not affected when autophagic ﬂux
was impaired (cells numberx10
5: Scrambled, 8.5±0.69;
siBeclin, 7.8±0.49; siLAMTOR1, 4.2±0.55; siLAMTORþ
siBeclin, 3.9±0.39. Values are means±S.E.M.). Similar
results were obtained upon ATG5 silencing (Supplementary
Figure S3). Thus, the stimulated autophagic ﬂux does not
contribute signiﬁcantly to ROS production.
ROS are causative in LAMTOR1 depletion-induced
apoptosis. Lysosomal ROS generation can cause lysoso-
mal membrane permeabilization (LMP), whereby lysosomal
cathepsins are released from the lysosomal lumen to the
cytosol and can trigger cell death.
26,27 However, the absence
of diffuse cathepsin D staining in the cytosol, a translocation
that is widely used to monitor lysosomal membrane
permeabilization,
26 suggested a conserved integrity of
lysosomal membranes (see Figure 3b and Supplementary
Figure S4 for a time course study). Even though we cannot
exclude the presence of LMP at levels below the detection
limit of the assay, this nonetheless contrasts with the readily
detectable cytoplasmic cathepsin D staining upon positive
control for partial LMP (Supplementary Figure S4).
To ascertain the causal relationship between lysosomal ROS
production and p53 activation, we treated cells with 2.5mMC Q
that inhibits ROS production, as depicted in Figure 4a. This CQ
concentration substantially reduced LAMTOR1 depletion-
induced apoptosis (Figure 5a), and p53
þ/þ HCT116 cell death
(Supplementary Figure S2D). Thus, the inhibition of ROS
production correlates with reduced apoptosis. Then, we
investigated the effect of the widely used radical-scavenging
vitamine E derivative 6-hydroxy-2,5,7,8-tetramethyl-chroman-
2-carboxylic acid (Trolox, Sigma, Saint Quentin Fallavier,
France).
28 Trolox prevented both p53 and p21 increase
following LAMTOR1 depletion (Figure 5b, and Supplementary
Figure S2E). Furthermore, Trolox treatment could partially
protected SHEP cells from LAMTOR1 depletion-induced death
(Figure 5c). Therefore, these data indicate that ROS production
mediates, at least in part, p53-induced apoptosis.
Discussion
In this study, we show that LAMTOR1 depletion leads to p53-
dependent apoptosis due to a deregulated lysosomal cata-
bolism and ROS production.
The downregulationofLAMTOR1protein results ina strong
increase in lysosomal structures and in their dispersion
throughout the cytoplasm. The subcellular distribution of
Figure 5 ROS are causative in LAMTOR-1 depletion-induced cell death.
(a) Representative FACS analysis of Annexin V/PI-stained cells. SHEP cells
transfected with scrambled or LAMTOR1 (A) siRNAs were treated or not with
2.5mM of CQ for 72h; n¼3. **Po0.01 using Mann–Whitney test. (b) SHEP cells
transfected with the indicated scrambled or LAMTOR1 (B) siRNAs, were treated or
not with anti-oxydant TROLOX at the indicated concentrations, for 72h. The
expressionlevelsofP53,P21,cathepsinD,LAMTOR1andactinweremeasuredby
westernblotting;n¼3.(c)SHEPcellstransfectedwith scrambled orLAMTOR1(B)
siRNAs were treated or not with TROLOX (500nM) for 72h, and viable cells were
counted. Values are meanþS.E.M. of three independent experiments. **Po0.01
using Mann–Whitney test
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Cell Death and Diseaselysosomes depends on their being transported along micro-
tubules.
29,30 However,Takahashi etal.
10reported thatvesicle
movement is not affected in LAMTOR
 /  mouse embryonic
ﬁbroblasts cells and that dispersion is more likely due to
defects in lysosomal maturation. Regardless of the explana-
tion for how lysosomes become scattered, the alteration in
lysosome positioning can be associated with certain dysfunc-
tions.
4–6,10 Interestingly, we found that these scattered
lysosomal structures remain nonetheless overall functional.
The assessment of cathepsin D maturation reveals no major
defect in late endocytic trafﬁcking or perturbed lysosomal
maturation. Furthermore, we observed an increase in
autophagic ﬂux, indicating that the fusion of autophagosomes
with lysosomes and the subsequent degradation of autopha-
gic cargo are not substantially altered. Consistent with these
ﬁndings, it has been reported that although depletion of
Huntingtin or Dynein disperses the endosomes and lyso-
somes through the cytoplasm, only minor defects in intracel-
lular trafﬁcking are observed.
31 Thus, LAMTOR1-depleted
cells cope with a lysosomal enhancement.
How LAMTOR1 regulates lysosomal activity is unclear at
present. The altered positioning of lysosomes on its own may
not be sufﬁcient to trigger an aberrant lysosomal catabolism.
Indeed, the downregulation of mTORC1 activity has been
implicated in lysosomal scattering,
10 but we have shown that
mTORC1 inhibition is not sufﬁcient to trigger p53 activation.
Furthermore, we have found that the silencing of Huntingtin,
which compromised intracellular vesicular trafﬁcking, did not
lead to cell death in SHEP cells (data not shown). A lysosomal
enhancement is often observed in neurodegenerative diseases
where it is sought to represent a compensatory response to
promote the clearance of toxic protein accumulation.
32 It is
possible that the increased macropinocytosis associated with
LAMTOR1 depletion
8 together with the altered lysosomal
positioning, results in an accumulation of endocytic material
that triggers such a compensatory response.
In order to investigate whether LAMTOR1’s expression is
alteredinsomeneurodegenerativediseases,weanalyzedthe
European bioinformatics institute (EBI) center databases,
which contained studies (E-GEOD-3790) (E-AFMX-6) show-
ing that LAMTOR10s expression is clearly and signiﬁcantly
decreasedinHuntington’s disease(t-test¼ 3,P¼0.035).
33
Furthermore, another study published in the EBI database
(E-GEOD-7307) shows that LAMTOR10s expression in
Parkinson’s disease decreases signiﬁcantly (t-test¼ 7.1,
P¼1.71 10
–10). These ﬁndings, together with our results,
supporta potential role forLAMTOR1 in the apoptotic process
of some neurons induced in certain neurodegenerative
disease. It is of note that enhancement of lysosomal activity
has been proposed as a treatment strategy against certain
neurodegenerative diseases.
32 Our results call for caution in
developing such potential treatment as, at least in certain
contexts exempliﬁed by LAMTOR1 depletion, lysosomal
enhancement can lead to cell death.
Even though macroautophagy proceeded normally, we
have nonetheless investigated whether mitophagy was
compromised upon LAMTOR1 silencing. As shown in
Supplementary Figure S5, mitophagy was unaffected, and
therefore did not contribute to ROS production. In addition to
mitochondria, lysosomes are now recognized as independent
intracellular sources of ROS.
23,24 The current view is that
ROS are produced by the speciﬁc activity of lysosomes such
as the redox action of iron, through the catalysis of Fenton-
type reactions. The use of low doses of the lysosomal inhibitor
CQ to limit lysosomal catabolism revealed that the expansion
of functional lysosomes generates excessive ROS produc-
tion. Noticeably, this increased ROS production does not
require the implementation of autophagy, indicating that the
autophagic catabolism does not contribute signiﬁcantly to
ROS production in this system. In turn, ROS that are known to
regulate p53 function through multiple mechanisms,
34 lead to
p53-dependent apoptosis. It is well described that ROS can
disrupt the integrity of the lysosomes, and that this LMP then
triggers caspase-mediated apoptosis or cathepsin-mediated
necrotic cell death.
26,27 However, we did not ﬁnd strong
evidence for LMP in our studies. Whether there is some LMP
that is below the detection limit of our assays remains formally
possible. Nevertheless, because LMP was readily detectable
in positive controls, these results suggested that lysosmal
membranes are more stable upon LAMTOR1 depletion. In
supportofthis, it hasbeen reported that lysosomalmembrane
stability increases upon cholesterol accumulation,
35 and we
and others have demonstrated that LAMTOR1 depletion
resulted in increased intracellular levels of cholesterol.
8,10
Thus, LAMTOR1 downregulation affects the tuning of
lysosomal activation, which can trigger a ROS-p53-depen-
dent apoptosis. We anticipate that these ﬁndings will be of
importance to better understand the pathologies associated
with lysosomal dysfunction.
Materials and Methods
Materials and reagents. Peroxidase-conjugated goat anti-mouse and anti-
rabbit IgG, and Cy3-conjugated donkey anti-mouse IgG were from Jackson
Immuno-Research (Suffolk, England, UK). The primary antibodies included anti-
lamp-1 (H4A3, Developmental Studies Hybridoma Bank, Iowa City, IA, USA), anti-
cathepsin D (Ab-2, Calbiochem, Saint Quentin en Yvelines, France), anti-p62
(SQSTM1, Enzo, Villeurbane, France), anti-LC3 (51–11, MBL International
Corporation, Nanterre, France), anti-p53 (D0–7, DAKO), anti-Beclin (E-8, Santa-
Cruz, Le perray en Yvelines, France), anti-ATG5 (D1G9, Cell Signaling, Montigny
le Bretonneux, France), anti-p21 Waf1/Cip1 (DCS60, Cell Signaling), anti-Raptor
(24C12, Cell Signaling), anti-Rictor (53A2, Cell Signaling), and anti-BrdU (3D4,
ﬂuorescein isothiocyanate (FITC)-conjugated, Pharmingen, Le pont de Claix,
France). Anti-LAMTOR-1 (rabbit pAb) was developed in collaboration with
Eurogenetec. The reagents included Trolox ((±)-6-Hydroxy-2,5,7,8-tetramethyl-
chromane-2-carboxylic acid (Sigma)), CQ diphosphate salt (Sigma), Lumi-light
western blotting substrate (Roche, Meylan, France), human Annexin V-FITC Kit
(AbCys SA, Les Ulis Courtaboeuf, France), and propidium iodide (PI, Sigma).
Cells culture. SHEP cell line is a clone derivative of the neuroblastoma cell
line SK-N-SH
36 that lacks most neuronal characteristics and has a wild-type
p53.
37 SHEP cells were grown in RPMI-1640 (Invitrogen, Saint Aubin, France)
supplemented with 10% heat-inactivated fetal calf serum (Lonza, Basel,
Switzerland) and antibiotics. Human colon carcinoma HCT116 p53
þ/þ and
p53
 /  cells were cultured in Macoy0s medium (Invitrogen) supplemented with
10% heat-inactivated fetal calf serum. MCF10-A ShCtrl, ShRictor, and ShRaptor
cells lines were cultured as described.
38
SiRNA & ShRNA gene knockdown. Cells were transfected with
nonspeciﬁc scrambled siRNA (siRNA#3, Dharmacon, Villebon sur Yvette, France),
or LAMTOR1 siRNA A (50-GGAGCUGGUUGUACAGUUU-30), LAMTOR1 siRNA B
(50-CAGCCAGCAACAUCAUUGAUU-30), or a pool of LAMTOR1 siRNA A and B,
by Hiperfect transfection reagent (QIAGEN, Les Ulis, France) according to the
manufacturer’s instructions. Experiments were repeated using alternatively siRNA
A or B, or the A/B pool. ShCtrl (Addgene plasmid 1864), ShRaptor (Addgene
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Cell Death and Diseaseplasmid 1857) and ShRictor (Addgene plasmid 1853) plasmids were obtained from
Dr. DM Sabatini laboratory.
15 MCF10-A cells expressing the different shRNAs
were established according to Addgene’s instructions and as described.
15
Apoptosis assays. In all, 2 10
5 cells were plated in six-well plates such
that cells would be 50% conﬂuent the following day at the time of transfections
and/or treatments. For analysis, ﬂoating and adherent cells were collected and
centrifuged 5min at 1000r.p.m. The cell pellet was re-suspended in Annexin V/PI
labeling solution according to the manufacturer0s instructions, and analyzed by
ﬂuorescence-activated cell sorting (FACS).
ROS assay. ROS were monitored by treating cells with 10mM H2.DCFDA
(Molecular Probes, Saint Aubin, France) in complete medium, for 20min. Cells
were then harvested, washed twice with phosphate-buffered saline (PBS) containing
10% heat-inactivated fetal calf serum, re-suspended in 200ml of PBS and analyzed
by FACS.
Transmission electron microscopy. Transfected cells were ﬁxed by
adding 4% glutaraldehyde in cell culture medium for 15 min at 41C. Fixation was
completed with 4% glutaraldehyde–0.2 M Na-cacodylate/HCl buffer at pH 7.4 for
30min at 41C and samples were washed three times with a 0.2 M Na-cacodylate/
HCl buffer at pH 7.4 and 0.4M saccharose solution for 30min. Cells were then
post-ﬁxed in 2% OsO4–0.3M Na-cacodylate/HCl buffer at pH 7.4 for 45 min at
41C, dehydrated in graded ethanol (5min in 30%, 50 and 70% ethanol, 15min in
95% ethanol and three times for 15min in pure ethanol), and embedded in Epon.
Ultrathin sections were cut with a RMX-MTL Ultramicrotome (VENTANA, Illkirch,
France), contrasted with methanolic uranyl acetate and lead citrate, and then
examined using a JEOL 1200 EX transmission electron microscope equipped with
MEGAVIEW II SIS camera (Olympus SIS-ELOI ¨SE, Roissy, France) and AnalySIS
software (Olympus SIS-ELOI ¨SE).
Immunoﬂuorescence. Immunostaining was performed as described.
8
Primary antibody used to label cathepsin D was revealed by incubation with Cy5-
Conjugated anti-mouse secondary antibody. Fixed cells were examined under a
Leica DMRB (Leica, Nanterre, France) for conventional immunoﬂuorescence, or
under a Leica TCS-SP confocal microscope (Leica) for confocal analysis and sections
were constructed with Leica Confocal Software (Leica). Fluorescence signals were
recorded using a 63X Plan-NEOFLUAR oil immersion objective (Leica).
Cell cycle assay. Treated cells were incubated in RPMI medium containing
BrdU (1:1000) for 1h at 371C and 5% CO2. After washing with PBS, cells were
ﬁxed with cold Ethanol 70% at 41C for 20min and incubated at room temperature
sequentially with HCL3N (20min), Borax (0,1M, 3min), and anti-BrdU-FITC
(20min). Then cells were re-suspended in Propidium Iodide buffer (RNAse
bufferþPI 5%þRNAse 5%) and analyzed by FACS.
Proliferation assay. Cells were collected and re-suspended in PBS. Dead
cells were stained by trypan blue 0,04%. The numbers of living cells were
determined using the Countess Automated Cell Counter (Invitrogen).
Mitochondrial integrity. Treated cells were stained with MitoTraker deep
red (50nM, Invitrogen) for 30min at 371C. After a wash with serum-free medium,
cells were harvested, washed twice with PBS, re-suspended in PBS containing 1%
heat-inactivated fetal calf serum and analyzed by FACS to assess levels of
mitochondrial function and integrity.
39
Western blotting analysis. Cells were lysed as described
8 and proteins
were separated on 10–15% SDS–PAGE. Immunoblotting was performed using
primary antibodies dilutions according to the manufacturer0s instructions.
Secondary antibody horseradish peroxidase conjugates were used at 1:10000.
Blots were developed using the lumi-light western blotting substrate.
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